Clinical evaluation on efficacy and safety of nateglinide in the treatment of type 2 diabetes / 中国基层医药
Chinese Journal of Primary Medicine and Pharmacy
;
(12): 2271-2273, 2013.
Artigo
em Chinês
| WPRIM
| ID: wpr-438132
ABSTRACT
Objective To evaluate the efficacy and safety of nateglinide,a new antidiabetic agent,in the treatment of type 2 diabetes.Methods 276 patients with type 2 diabetes mellitus,in accordance with the table of random number method,were divided into the nateglinide group 138 cases,repaglinide group 138 cases.The nateglinide group was given 30 mg nateglinide,and repaglinide group was given 0.5 mg repaglinide,3 times a day,oral administration 15min before meal.12 weeks for one period of treatment.FBG,2h PBG,HbAlc and security index were detected before and after treatment.Results After treatment,FBG,2h PBG and HbAlc indexes in the two groups were lower than before treatment,the differences were statistically significant(all P < 0.05).The differences were not significant compared between the two groups (all P > 0.05).No serious adverse events occurred in two groups.Conclusion Nateglinide can effectively control fasting and postprandial blood sugar in patients with type 2 diabetes.It is safe and reliable and worthy clinical promotion.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Idioma:
Chinês
Revista:
Chinese Journal of Primary Medicine and Pharmacy
Ano de publicação:
2013
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS